Latest Reported Offering
$50,000
Target Amount
$1,200,000
Maximum Amount
2026-12-31
Deadline
Security Details
Type: Preferred Stock
Price per share: $3.47
Price set by: Dividing pre-money valuation $87,900,000.00 by number of shares outstanding on fully diluted basis.
Shares offered: 14,410+
Offering Costs
Cash commission: 5%
of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.
Equity compensation: —
No
Filing history
Form C family — 1 filingThe reported figures behind Mahzi Therapeutics, Inc.
Form C prints a most-recent and a prior fiscal year side by side but never names them. The dashboard chains every filing into those years and plots them. EDGAR still has each Form C-AR; the dashboard lays every year they filed next to it.
- Reported financials chained into fiscal years — revenue, income, assets, cash — not one filing at a time
- A sparkline on each figure so the shape is visible before the numbers
- A revenue series dated to the filings that reported it
- The campaign as filed: target, ceiling, deadline, and the portal that ran it
- Follow it, and see it change on your watchlist
Part of the Alts plan — $40/mo at launch pricing ($100 list)
Company Information
Legal Status
Corporation
Jurisdiction
Delaware
Date of Incorporation
2020-06-30
Website
Latest Metrics
Employees14
Total Assets$11,638,540
Cash on Hand$10,695,753
Revenues$0.00
Net Income-$18,656,306
Crowdfunding Portals
The intermediary named in this company’s Form C filings. Investments in a Regulation Crowdfunding offering can only be made through them.